Maxim Group Starts BeiGene, Ltd. (BGNE) at Buy

September 21, 2016 5:39 PM EDT
Get Alerts BGNE Hot Sheet
Price: $32.91 -1.08%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 27 | New: 7
Trade BGNE Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Maxim Group initiates coverage on BeiGene, Ltd. (NASDAQ: BGNE) with a Buy rating and a price target of $41.00.

Analyst Gabrielle Zhou commented:

  • BeiGene's BTK inhibitor (BGB-3111) is going pivotal. We view 3111 as a de-risked, high-value asset in the rich BTK world of therapeutic kinases. Recall that Imbruvica (AbbVie) is indicated for multiple hematological malignancies. The compound was acquired through the $21B acquisition of Pharmacyclics. AstraZeneca recently acquired 55% ownership of Acerta, driven by interest in its BTK inhibitor, for $4B. As such, we can argue that 3111, based on its clinical profile and scarcity value, supports BeiGene's valuation and potential as the company works to bring the next BTK to market.
  • Not just BTK, but a PD-1 too. We believe that, ultimately, PD-1 checkpoint antibodies could emerge as the largest new drug class in oncology, with each checkpoint entering the space (just as we see in other therapeutic areas) exhibiting nuanced differences. As such, we see value in BeiGene's humanized PD-1 (BGB-A317) as a potentially differentiated checkpoint and one with access to the domestic Chinese marketplace. A317 is currently in dose-escalating studies and is being evaluated as both a monotherapy and in combination (BTKs).
  • Bottom line. BeiGene, as a China-based company, brings unique advantages in the ability to commercialize its own pipeline in the country. The company staffs a fully integrated R&D center in Beijing and a manufacturing plant in Suzhou, with operations centers in both Beijing and Shanghai.

For an analyst ratings summary and ratings history on BeiGene, Ltd. click here. For more ratings news on BeiGene, Ltd. click here.

Shares of BeiGene, Ltd. closed at $30.98 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

New Coverage

Related Entities

Maxim Group, Definitive Agreement

Add Your Comment